Local News

• Corn farmers who use Monsanto advanced technology eligible for lower insurance premiums  Farmers in 11 states who plant a majority of their corn acres using hybrid seeds featuring YieldGard Plus with Roundup Ready Corn 2, YieldGard VT Triple and YieldGard VT Triple PRO technology from Monsanto Company will have an opportunity to lower their crop insurance premiums in 2009.
  Monsanto Company August 19, 2008  
• Patient side point-of-care testing enables quicker treatment decisions  Patient side point-of-care testing - where diagnostic testing is conducted at or near the site of the patient - enables doctors to make decisions on patients presenting with chest pain up to 20 minutes faster than those whose lab tests are evaluated by a standard lab.
  Abbott August 19, 2008  
• BMS and PDL BioPharma enter alliance to develop novel treatment for multiple myeloma  Bristol-Myers Squibb Company and PDL BioPharma announced an agreement for the global development and commercialization of PDL BioPharma's anti-CS1 antibody, elotuzumab, previously known as HuLuc63, currently in Phase I development for multiple myeloma.
  Bristol-Myers Squibb Company August 19, 2008  
• Abbott and AstraZeneca expand relationship to include co-promotion of CRESTOR(R)  Abbott and AstraZeneca announced that they have entered into an agreement for Abbott to promote AstraZeneca's CRESTOR(R) (rosuvastatin calcium), a medication used along with diet to reduce high cholesterol.
  Abbott August 14, 2008  
• Pfizer says vacation with your dog before the summer ends  With canine motion sickness the leading reason pet owners are not able to take their dogs on day trips or vacation, Pfizer is encouraging more people to talk with their veterinarians about managing travel with their dog before the summer ends.
  Pfizer Inc. August 14, 2008  
• Meridian Bioscience provides sales and earnings guidance for fiscal 2009  Meridian Bioscience provided the financial community with guidance regarding the Company's fiscal 2009 sales and earnings estimates. Based on the Company's business planning for the fiscal year ending September 30, 2009, management expects net sales to be in the range of $157 to $160 million.
  Meridian Bioscience, Inc. August 14, 2008  
• Northfield Laboratories reports fiscal 2008 fourth quarter and year-end financial results  Northfield Laboratories announced that it has filed its Annual Report on Form 10K, letter from the Chairman, and final Proxy Statement with the Securities Exchange Commission.
  Northfield Laboratories Inc. August 14, 2008  
• NeoPharm announces second quarter 2008 financial results  NeoPharm announced its second quarter 2008 financial results. For the second quarter ended June 30, 2008, NeoPharm reported a net loss of $2.1 million, or ($0.07) per basic and diluted share, as compared to a net loss of $3.6 million, or ($0.13) per share, for the same period last year.
  NeoPharm, Inc. August 14, 2008  
• Genentech rejects takeover bid from Roche  Roche is expected to increase its offer for the biotechnology company Genentech now that an initial $43.7 billion bid has been rejected, analysts said. Genentech said that a special committee of directors had found that Roche's offer "substantially undervalues the company."
  The New York Times August 13, 2008  Andrew Pollack
• Bayer’s annual report receives international praise  Praise all around for Bayer's Annual Report 2007: It received gold, silver, bronze and honors twice each in the recently concluded Annual Report Competition (ARC).
  Bayer August 12, 2008  

   (next 10 articles)